• What is CMT?
    • About CMT
    • Type1
      • What is CMT1A?
      • What is CMT1B?
      • What is CMT1E?
      • What is HNPP?
    • Type2
      • What is CMT2A?
    • Type4
      • What is SORD?
    • TypeX
      • Understanding CMT1X/CMTX1 and GJB1
    • —-
    • Watch Our Video Series
    • Learn About Treatments in Development
  • Research
    • Research Approach
    • Research Projects We Fund
    • Research Pipeline
    • Gene Therapy
    • Clinical Trials
    • —-
    • Apply for Funding
    • Emerging Researcher Award
  • News & Stories
    • News
    • CMT Stories
  • Take Action
  • About Us
    • Who We Are
    • Board of Directors
    • Research Advisory Council
    • Scientific Advisory Board
    • Research Foundation Staff
    • Events
    • Financials
    • Contact Us
    • Velocity
    • Global CMT Research Convention
  • Donate
Initial CMTRF Funding Leads Augustine Therapeutics to Raise $85 Million for CMT Clinical Trials

Initial CMTRF Funding Leads Augustine Therapeutics to Raise $85 Million for CMT Clinical Trials

Mar 27, 2025 | CMT Research Updates, CMTRF Funded Research, Research News

CMT Research Foundation funded partner Augustine Therapeutics recently announced that they completed their Series A financing round and raised $85 million, which will be used to advance their Charcot-Marie-Tooth disease drug candidate, AGT-100216, through a Phase I/II...
More Than Just a Rare Disease: Jodi Balog’s Journey With CMT

More Than Just a Rare Disease: Jodi Balog’s Journey With CMT

Feb 27, 2025 | Life with CMT

Jodi Balog, Pennsylvania, Living With CMT Jodi Balog has lived with Charcot-Marie-Tooth disease for more than 30 years. Diagnosed at the age of 13, CMT has become all she’s ever known. While CMT is classified as a rare disease, for Jodi — and millions of others — it’s...
Dr. Afrooz Rashnonejad Joins CMTRF’s Scientific Advisory Board

Dr. Afrooz Rashnonejad Joins CMTRF’s Scientific Advisory Board

Jan 23, 2025 | Foundation News

CMT Research Foundation is pleased to announce that Dr. Afrooz Rashnonejad has joined the Foundation’s Scientific Advisory Board. The SAB is composed of distinguished scientific and clinical experts specializing in Charcot-Marie-Tooth disease and drug development. The...
NMD Pharma Announces FDA Orphan Drug Designation for NMD670

NMD Pharma Announces FDA Orphan Drug Designation for NMD670

Jan 9, 2025 | CMT Research Updates, Research News

NMD Pharma has announced that they have been granted orphan drug designation by the Food and Drug Administration for NMD670, their novel, oral, small molecule inhibitor of the skeletal muscle-specific chloride ion channel ClC-1, for the treatment of...
Maintaining Momentum: CMTRF’s Vision for 2025 and Beyond

Maintaining Momentum: CMTRF’s Vision for 2025 and Beyond

Jan 7, 2025 | Foundation News

Greetings and Happy New Year to you all. When I began my tenure as CEO of the CMT Research Foundation in October 2024, I was immediately inspired and impressed by the work of the Foundation. I was equally moved by the dedication of the greater CMT community,...
« Older Entries
Next Entries »

Search Articles

Categories

  • About CMT
  • CMT Research Updates
  • CMTRF Funded Research
  • Drug Development
  • Foundation News
  • Life with CMT
  • Research News

Help us find a cure.

Donate Now
Donate Now

Help us find a cure.

NEWSLETTER SIGNUP

Stay up to date on new CMT research, treatments and clinical trials



Address

4062 Peachtree Road
Suite A209
Atlanta, GA 30319



Phone Number

404.806.7180



EMAIL

[email protected]

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2025 CMT Research Foundation | Privacy Policy

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}